论文部分内容阅读
目的探讨早期使用人血清蛋白治疗高危新生儿的疗效。方法选取2012年3月—2013年9月出生的高危新生儿49例,随机分为干预组(25例)与对照组(24例)。对照组予以常规治疗,干预组在对照组基础上早期使用人血清蛋白治疗。观察两组患儿并发症发生情况、并发症持续时间及住院时间。结果干预组患儿硬肿、黄疸、肺炎、缺血缺氧性脑病、败血症发生率低于对照组,差异有统计学意义(P<0.05);干预组患儿硬肿、黄疸、肺炎、败血症持续时间及住院时间短于对照组(P<0.05)。结论早期使用人血清蛋白治疗高危新生儿的疗效显著,并发症少,有利于患儿康复。
Objective To investigate the early use of human serum albumin in the treatment of high-risk neonates. Methods Forty-nine high-risk neonates born from March 2012 to September 2013 were randomly divided into intervention group (n = 25) and control group (n = 24). The control group was routinely treated, and the intervention group was treated with human serum albumin early on the basis of the control group. The incidence of complications, duration of complications and length of hospital stay in both groups were observed. Results The incidence of edema, jaundice, pneumonia, hypoxic-ischemic encephalopathy and sepsis in the intervention group was significantly lower than that in the control group (P <0.05). In the intervention group, children with edema, jaundice, pneumonia and septicemia Duration and hospital stay were shorter than those in the control group (P <0.05). Conclusion The early use of human serum albumin in the treatment of high-risk neonates has obvious curative effect and few complications, which is good for the recovery of children.